focus -WSS

focus

author：knowledge 2025-09-30 20:17:53 - browse：9652

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

Wikipedia

WSS

New definition of a human embryo proposed amid rapid advances

The untold story of TV’s first prescription drug ad

The pain doctors face in trying to build their families

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Harvard's David Sinclair gets blowback over aging

The boys, now 6, who are gene therapy’s ‘edge case’ problem

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Bright Health sells Medicare Advantage business to Molina

Ancient Greek ideas underpin modern concepts of pregnancy

23andMe had bad news about my health. I wish a person had delivered it

Patient advocates sound warning on FDA proposal on salt intake

Heart attack and stroke risk calculators need revising

Lung cancer is America's deadliest cancer. Yet so few get screened

Medical leaders decry Supreme Court decision on affirmative action

Change Healthcare: What is it, why does its cyberattack matter?

Alkermes shareholders re

New details revealed about Purdue's marketing of OxyContin

explore

Readout Newsletter: BridgeBio, Akero, and human embryo models

Harvard's David Sinclair gets blowback over aging

Evacuations in place as 3 wildfires burn in eastern Washington state

Families look for replacement for GSK asthma drug Flovent

Ukraine taking heavy casualties 10 weeks into its counteroffensive

Harvard's David Sinclair gets blowback over aging

hotspot

focus

Wikipedia

explore